HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). This virus has become a global pandemic with unprecedented mortality and morbidity along with attendant financial and economic crises. Furthermore, COVID-19 can easily be transmitted regardless of religion, race, sex, or status. Globally, high hospitalization rates of COVID-19 patients have been reported, and billions of dollars have been spent to contain the pandemic. Angiotensin-converting enzyme (ACE) 2 is a receptor of SARS-CoV-2, which has a significant role in the entry of the virus into the host cell. ACE2 is highly expressed in the type II alveolar cells of the lungs, upper esophagus, stratified epithelial cells, and other tissues in the body. The diminished expressions of ACE2 have been associated with hypertension, arteriosclerosis, heart failure, chronic kidney disease, and immune system dysregulation. Overall, the potential drug candidates that could serve as ACE2 activators or enhance the expression of ACE2 in a disease state, such as COVID-19, hold considerable promise in mitigating the COVID-19 pandemic. This study reviews the therapeutic potential and pharmacological benefits of the novel ACE2 in the management of COVID-19 using search engines, such as Google, Scopus, PubMed, and PubMed Central.
AuthorsAdemola Adetokunbo Oyagbemi, Temitayo Olabisi Ajibade, Yapo Guillaume Aboua, Idayat Titilayo Gbadamosi, Aduragbenro Deborah A Adedapo, Abimbola Obemisola Aro, Olumuyiwa Abiola Adejumobi, Emma Thamahane-Katengua, Temidayo Olutayo Omobowale, Olufunke Olubunmi Falayi, Taiwo Olaide Oyagbemi, Blessing Seun Ogunpolu, Fasilat Oluwakemi Hassan, Iyanuoluwa Omolola Ogunmiluyi, Olufunke Eunice Ola-Davies, Adebowale Benard Saba, Adeolu Alex Adedapo, Sanah Malomile Nkadimeng, Lyndy Joy McGaw, Prudence Ngalula Kayoka-Kabongo, Momoh Audu Yakubu, Oluwafemi Omoniyi Oguntibeju
JournalVeterinary world (Vet World) Vol. 14 Issue 10 Pg. 2705-2713 (Oct 2021) ISSN: 0972-8988 [Print] India
PMID34903929 (Publication Type: Journal Article, Review)
CopyrightCopyright: © Oyagbemi, et al.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: